Biotech Start-up Hits Out At Flu
British biotech start-up, Covimro, has developed a food-grade compound that may be able to combat viruses, such as the seasonal flu.
Covimro demonstrated efficacy against the flu virus in an animal model study carried out by A-IR Clinical Research and Pharmidex Pharmaceutical Services.
A statement detailing the research, read as follows: “The… testing analysed Covimro’s antiviral capability against an infection of Influenza A H3N2, a flu variant consistent with the seasonal, non-lethal viruses familiar to humans. Once induced, the control group of mice subjects saw the virus replicate quickly, infiltrating their airways and manifesting in comprehensive weight loss.
“Subjects receiving the Covimro treatment trended toward a drastic reduction of the infected cells that replicate within the lungs and inflame the airways. This effectively slowed replication and shielded against the drastic weight loss experienced by the control group.”
Dr. Ross Walton, Respiratory Immunologist, A-IR Clinical Research Ltd discussed the research. He said: “In a pre-clinical model of influenza infection bearing many hallmarks of seasonal flu mediated clinical disease, daily oral Covimro treatment was shown to significantly reduce virus replication.”
According to a statement from Covimro, these are only the latest breakthroughs in assessing the possibilities of the treatment. They are also currently doing research on its effectiveness towards other viruses.
James Lindberg, COVIMRO Ltd, Founder and CEO talked about the aims of the company.
He said: “The desire to create solutions that can knock out any enveloped virus with zero to minimal side effects is the driving force behind Covimro. The required hallmark for any therapeutic or drug is indeed safety and efficacy. Covimro™ delivers both with unparalleled results, placing us at the forefront of exploring what this exciting new technology can offer.”
The company is currently in a seed investment funding round.